In the third episode of the series with Perry N. Halkitis, PhD, MS, MPH, he discusses how human behavior as well as other factors play a significant role in repeating outbreaks.
|Videos|March 8, 2021
Looking at an Investigational PrEP Treatment With an Implant Option
Author(s)John Parkinson
Merck has developed its investigational islatravir subdermal implant for prevention of HIV infection, and it is going to be studied for a long-term delivery of up to 1 year.
Advertisement
Merck’s islatravir (formerly MK-8591) is an investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI) being studied for both PrEP and HIV therapy. With regards to PrEP, the company is planning to study its islatravir subdermal implant for the possibility of 1 year of therapy.
"I think a yearly implant will be an attractive option for many people,” trial investigator Randolph Matthews, MD, PhD, senior principal scientist, Merck, said. “We are looking at a scenario over the next several years where people who are interested in PrEP, will have several different options.”
He says the therapy has a high potency and long half-life which makes it possible to look at long-term delivery.
Earlier today, Merck reported results from its phase 1 trial of its islatravir subdermal implant for HIV prevention. It was a double-blind placebo-controlled multicenter phase 1 trial, studying a single islatravir-eluting (48 mg, 52 mg or 56 mg) or placebo implant, which was placed in participants at low risk of HIV infection for 12 weeks.
The company said the investigational therapy demonstrated that the implant achieved active drug concentrations above the pre-specified pharmacokinetics (pk) threshold at 12 weeks across the three doses of islatravir studied (48 mg, 52 mg and 56 mg).
Safety and tolerability, as well as PK for islatravir parent and islatravir-TP from plasma and PBMCs, was collected throughout placement and for 8 weeks post removal.
The data was presented during the
In this second segment of an interview with Contagion, Matthews talks about PrEP treatment options and what they are doing to get ready for a phase 2 trial.
Advertisement
Related to this article
In the second episode of the series with Perry N. Halkitis, PhD, MS, MPH, he brings his personal experience to this topic and questions whether there should be a shift in who manages the primary care needs of these patients.
In the first episode of our news series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates, and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
Food expert Lynette Johnston, PhD, provides some context around the ongoing outbreak, discusses prevention, and compares 2026 food recalls with previous years.
Here is a review of glucagon-like peptide-1 receptor agonist use in people with HIV.
The Peggy Lillis Foundation will host its 17th Annual Changing the Odds Gala this month in New York City, and it will include a casino, fellowship amongst the C diff community, and an award ceremony honoring a physician-scientist, philanthropist, a researcher, and a patient advocate for their contributions to C difficile awareness, treatment, and prevention.
Resistance-guided testing targeting a single gene mutation could let clinicians safely reintroduce ciprofloxacin for the majority of gonorrhea cases still susceptible to it, sparing ceftriaxone as resistance climbs worldwide. Lao-Tzu Allan-Blitz, MD, MPH, offers insights into his work in this area.
The federal agency gave the nod for the smallest once-daily single tablet regimen available for virologically suppressed adults with HIV, including those on complex regimens. The approval is based on the results of the 2 phase 3 ARTISTRY trials.
Advertisement
Advertisement